Clinical trials: aldesleukin
Metastatic Clear Cell Renal Cell Carcinoma
High Dose IL-2 and Stereotactic Ablative Body Radiation Therapy for Metastatic Renal Cancer
In this i-SABR (immunotherapy + Stereotactic Ablative Body Radiation) trial, the stereotactic radiation to multiple metastatic sites is delivered not only to eradicate sites of bulky progressive disease, but also to provide…
- Trial name
- NCT01896271
- Testing
- IL-2, Stereotactic Ablative Body Radiation Therapy
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of Texas Southwestern Medical Center
Leukemia, Leukemia, Myeloid
Natural Killer Cell (CYNK-001) Infusions in Adults with AML
This study will find the maximum tolerated dose or the maximum planned dose of CYNK-001 which contains natural killer (NK) cells derived from human placental CD34+ cells and culture-expanded.
- Conditions
- Leukemia, Leukemia, Myeloid, Leukemia, Myeloid, Acute, Neoplasms by Histologic Type
- Trial name
- CYNK001AML01 (NCT04310592)
- Testing
- CYNK-001
- Where
- 10 sites in United States
- Volunteers
- 27 people
- Sponsor
- Celularity Incorporated
Endocrine/Neuroendocrine, Non-Small Cell Lung Cancer
Non-Viral TCR Gene Therapy
Background: A person s white blood cells can be modified in a lab to recognize certain changes in their tumor. Many of these cells are collected from the person, modified, then given back to the person.
- Conditions
- Endocrine/Neuroendocrine, Non-Small Cell Lung Cancer, Breast Cancer, Gastrointestinal/Genitourinary Cancers
- Trial name
- NCT04102436
- Testing
- Fludarabine, Cyclophosphamide, Aldesleukin
- Where
- United States
- Sponsor
- National Cancer Institute (NCI)
Neoplasms, Tumors
Laboratory-Treated Autologous Lymphocytes, Aldesleukin, and Sargramostim (GM-CSF) in Treating Advanced Solid Tumors
RATIONALE: Giving autologous lymphocytes that have been treated in the laboratory with antibodies may stimulate the immune system to kill tumor cells. Aldesleukin may stimulate the lymphocytes to kill tumor cells.
- Conditions
- Neoplasms, Tumors, Solid Tumors, Metastatic Cancer
- Trial name
- NCT01081808
- Testing
- EGFRBi-armed autologous activated T cells
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Roger Williams Medical Center
Leukemia
Combination Chemotherapy Plus PSC 833 Followed by Interleukin-2 in Treating Patients With Acute Myelogenous Leukemia
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Some cancers may become resistant to chemotherapy drugs.
- Trial name
- NCT00002925
- Testing
- ara-C, Daunorubicin, Etoposide
- Where
- 33 sites in United States
- Volunteers
- 410 people
- Sponsor
- National Cancer Institute (NCI)
Metastatic Melanoma
Chemotherapy, Irradiation, Cell Infusions, and Interleukin-2 to Treat Metastatic Melanoma
Background: In a study in humans with melanoma, patients given total body irradiation to suppress the immune system in conjunction with chemotherapy showed a significant clinical response.
- Trial name
- NCT00314106
- Testing
- Melanoma Reactive TIL, Cyclophosphamide, IL-2
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- National Cancer Institute (NCI)
Alzheimer Disease
Systemic and Central Inflammation in AD
Inflammation could provide a new focus for therapeutic intervention. In this study, we will measure blood and cerebrospinal fluid (CSF) inflammation biomarkers and compare them to measurements of brain glial activation obtained…
- Trial name
- NCT06384378
- Testing
- 11C-ER176
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- The Methodist Hospital Research Institute
Melanoma (Skin)
Cyclophosphamide, Fludarabine, and High-Dose Interleukin-2 in Treating Patients With Metastatic Melanoma
RATIONALE: Drugs used in chemotherapy, such as cyclophosphamide and fludarabine, work in different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00085423
- Testing
- aldesleukin, sargramostim, cyclophosphamide
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Dartmouth-Hitchcock Medical Center
Melanoma, Skin Cancer
Phase II Study of Metastatic Melanoma With Lymphodepleting Conditioning and Infusion of Anti-MART-1 F5 TCR-Gene-Engineered Lymphocytes
Background: Human peripheral blood lymphocytes have been engineered to express a T-cell receptor (TCR) that recognizes a blood type,HLA-A 0201 (human leukocyte antigen) derived from the gp100 protein.
- Trial name
- NCT00509288
- Testing
- autologous anti-MART-1 F5 T-cell receptor, Cyclophosphamide, Fludarabine
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- National Cancer Institute (NCI)
Clinical Stage IV Gastric Cancer AJCC v8, Gastric Adenocarcinoma
Aldesleukin With Nivolumab and Standard Chemotherapy for Treatment of Gastric Cancer With Peritoneal Metastasis
This phase Ib trial test effects of aldesleukin in combination with nivolumab and standard chemotherapy in treating patients with gastric cancer that has spread to the tissue lining of the abdomen (peritoneal metastasis).
- Conditions
- Clinical Stage IV Gastric Cancer AJCC v8, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Metastatic Gastric Carcinoma
- Trial name
- NCT05802056
- Testing
- Aldesleukin, Biopsy Procedure, Biospecimen Collection
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Mayo Clinic
HIV Infections
The Safety and Effectiveness of Interleukin-2 Plus Zidovudine in Patients With AIDS or AIDS Related Complex
To test the safety and tolerance of three different doses of recombinant human interleukin 2 (aldesleukin; IL-2), when it is given for five consecutive days to patients with AIDS or AIDS related complex (ARC), who have also…
- Trial name
- NCT00000986
- Testing
- Zidovudine, Aldesleukin
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Acute Coronary Syndromes
Low-dose Interleukin-2 for the Reduction of Vascular Inflammation in Acute Coronary Syndromes - IVORY
Acute coronary syndromes (ACS) result from coronary plaque(s) disruption, which initiates a thrombotic process leading to partial or complete obstruction of the vessel lumen with subsequent myocardial ischaemia and necrosis.
- Trial name
- IVORY (NCT04241601)
- Testing
- Interleukin-2 [IL-2]
- Where
- United Kingdom
- Volunteers
- 60 people
- Sponsor
- Cambridge University Hospitals NHS Foundation Trust
Melanoma
Cisplatin, Temozolomide, Abraxane, With Interleukin-2 and Interferon for Metastatic Melanoma
The goal of this clinical research study is to find the highest tolerable dose of Abraxane (nab-paclitaxel) when given in combination with cisplatin, Temodar (temozolomide), interferon alfa-2b, and interleukin-2 (IL-2) to…
- Trial name
- BCAA (NCT00970996)
- Testing
- Temozolomide, Abraxane, Cisplatin
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- M.D. Anderson Cancer Center
Brain and Central Nervous System Tumors
Cytotoxic T Cells and Interleukin-2 in Treating Adult Patients With Recurrent Brain Tumors
RATIONALE: Biological therapy uses different ways to stimulate the immune system and stop cancer cells from growing. Cytotoxic T cells combined with interleukin-2 may be an effective treatment for recurrent brain tumors.
- Trial name
- NCT00002572
- Testing
- aldesleukin, muromonab-CD3, therapeutic tumor infiltrating lymphocytes
- Where
- 3 sites in United States
- Volunteers
- 10 people
- Sponsor
- University of Colorado, Denver
Liver Transplantation
Efficacy of Low Dose, SubQ Interleukin-2 (IL-2) to Expand Endogenous Regulatory T-Cells in Liver Transplant Recipients
The purpose of this investigation is to study if very low dose IL-2, given to liver transplant patients by subcutaneous (under the skin) injections, over a 4 week period of time, will cause an increase in the number of Treg cells…
- Trial name
- NCT02739412
- Testing
- Interleukin-2
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Beth Israel Deaconess Medical Center
Leukemia, Myelodysplastic Syndromes
Cellular Adoptive Immunotherapy in Treating Patients With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndromes That Relapsed After Donor Stem Cell Transplant
RATIONALE: Biological therapies, such as cellular adoptive immunotherapy, stimulate the immune system in different ways and stop cancer cells from growing.
- Trial name
- NCT00107354
- Testing
- aldesleukin, therapeutic allogeneic lymphocytes, therapeutic autologous lymphocytes
- Where
- United States
- Sponsor
- Fred Hutchinson Cancer Center
Melanoma (Skin), Metastatic Cancer
Interleukin-2 With or Without Histamine Dihydrochloride in Treating Patients With Stage IV Melanoma Metastatic to the Liver
RATIONALE: Interleukin-2 may stimulate a person's white blood cells to kill tumor cells. Histamine dihydrochloride may help interleukin-2 kill more tumor cells by making tumor cells more sensitive to the drug.
- Trial name
- NCT00039234
- Testing
- aldesleukin, histamine dihydrochloride
- Where
- 19 sites in United States, Canada and 2 more
- Sponsor
- Maxim Pharmaceuticals
Sarcoma, Soft Tissue Sarcoma (STS)
A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Soft Tissue Sarcoma
A study of lifileucel (tumor-infiltrating lymphocytes) in adults with advanced soft tissue sarcoma ('SARATOGA')
- Conditions
- Sarcoma, Soft Tissue Sarcoma (STS), Advanced Soft Tissue Sarcoma, Undifferentiated Pleomorphic Sarcoma (UPS)
- Trial name
- 'SARATOGA' (NCT07741877)
- Testing
- Lifileucel
- Where
- 2 sites in United States
- Volunteers
- 80 people
- Sponsor
- Iovance Biotherapeutics, Inc.
Leukemia, Myelodysplastic Syndromes
Donor Umbilical Cord Blood Natural Killer Cells, Aldesleukin and Umbilical Cord Blood Transplant in Patients With Refractory Hematologic Cancers.
RATIONALE: Giving chemotherapy, natural killer cells, aldesleukin, and total-body irradiation before a donor umbilical cord blood stem cell transplant helps stop the growth of abnormal cells and cancer cells.
- Trial name
- NCT00354172
- Testing
- aldesleukin, filgrastim, natural killer cell (NK) therapy
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Kidney Transplantation
Ultra-low Dose Subcutaneous IL-2 in Renal Transplantation
To investigate the safety and tolerability of treatment with low dose rIL-2 in renal transplant recipients. To assess the immunologic impact of low dose rIL-2 in renal transplant recipients.
- Trial name
- NCT02417870
- Testing
- aldesleukin
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Anil K. Chandraker, MD